Nonketotic Hyperglycinemia is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.
Nonketotic hyperglycinemia (NKH), also known as glycine encephalopathy, is a rare autosomal recessive inborn error of metabolism characterized by impaired glycine cleavage and resulting in toxic accumulation of glycine in the brain and other tissues[1]. The disease typically presents in infancy with catastrophic neurological deterioration, including profound hypotonia, myoclonic seizures, and developmental arrest[2]. NKH represents one of the most devastating metabolic encephalopathies, with most affected individuals experiencing severe neurodevelopmental disability despite aggressive treatment[3].
Nonketotic hyperglycinemia is an extremely rare disorder with an estimated incidence of 1 in 60,000 to 1 in 76,000 live births[4]. The disease shows equal distribution between males and females with no ethnic predominance, though founder mutations have been identified in certain isolated populations[5]. The incidence is higher in populations with higher rates of consanguinity due to the autosomal recessive inheritance pattern[6]. Approximately 80% of NKH cases present within the neonatal period (classic neonatal form), while the remainder present in infancy or later childhood with milder phenotypes[7].
The glycine cleavage system (GCS) is a mitochondrial enzyme complex responsible for glycine catabolism. It consists of four protein components:
The GCS catalyzes the cleavage of glycine into CO₂, NH₃, and a one-carbon unit transferred to tetrahydrofolate, representing the major pathway for glycine degradation in mitochondria[12].
Mutations in any of the four GCS component genes can cause NKH:
| Gene | Protein | OMIM | Proportion of Cases |
|---|---|---|---|
| GLDC | Glycine decarboxylase | 238300 | ~70-80% |
| GCSH | H-protein | 238330 | ~10-15% |
| AMT | T-protein | 238310 | ~10-15% |
| GLY DLDH | L-protein | 238331 | <5% |
Over 300 disease-causing mutations have been identified, including:
Genotype-phenotype correlations exist: patients with two null mutations typically have the severe neonatal form, while those with at least one missense mutation may have milder presentations[14].
Glycine acts as both an inhibitory and excitatory neurotransmitter in the central nervous system:
In NKH, the excessive accumulation of glycine produces a paradoxical effect:
The pattern of brain injury in NKH reflects regional vulnerability to glycine toxicity:
Presentation occurs within the first days to weeks of life:
Onset between 1-6 months:
A rare variant where symptoms improve over time:
Very rare presentations in childhood or adulthood:
Sodium benzoate conjugates glycine in the liver, reducing plasma and CSF glycine levels:
Valproic acid should be AVOIDED as it inhibits mitochondrial glycine metabolism and may worsen symptoms[27].
Combination therapy may provide additional benefit:
Very low glycine diet may be beneficial:
The prognosis for classic NKH is poor:
Mild and transient forms may have better outcomes with early treatment[31].
Several mouse models recapitulate NKH:
Animal models have demonstrated:
Recent research on nonketotic hyperglycinemia has advanced understanding of glycine encephalopathy pathophysiology and potential therapeutic approaches.
Hamosh et al. Nonketotic hyperglycinemia (2002). 2002. ↩︎
Tress et al. Clinical spectrum of NKH (2011). 2011. ↩︎
Korman et al. Outcomes in NKH (2006). 2006. ↩︎
Lüthy et al. Incidence of NKH (1991). 1991. ↩︎
Nielsen et al. Founder mutations in NKH (2019). 2019. ↩︎
Boneh et al. Consanguinity and NKH (2008). 2008. ↩︎
Carson et al. Infantile form of NKH (1992). 1992. ↩︎
Kikuchi et al. Glycine decarboxylase (2008). 2008. ↩︎
Okamura-Ikeda et al. H-protein structure (2005). 2005. ↩︎
Koyata et al. T-protein function (1993). 1993. ↩︎
Perham et al. L-protein and GCS assembly (2000). 2000. ↩︎
Sershen et al. Glycine cleavage system (1976). 1976. ↩︎
Matsuo et al. Mutation spectrum in NKH (2020). 2020. ↩︎
Kure et al. Genotype-phenotype correlations (2006). 2006. ↩︎
Betz et al. Glycine receptors in CNS (1994). 1994. ↩︎
Johnson et al. [Glycine as NMDA co-agonist (1993)](https://doi.org/10.1016/0165-6147(93). 1993. ↩︎
Kurki et al. Glycine toxicity in NKH (2019). 2019. ↩︎
McDonald et al. NMDA receptors and excitotoxicity (1990). 1990. ↩︎
Shalak et al. Neuroimaging in NKH (2005). 2005. ↩︎
Schiffmann et al. Biochemical diagnosis of NKH (2019). 2019. ↩︎
von Spronsen et al. Classic neonatal NKH (2021). 2021. ↩︎
Hayasaka et al. Infantile NKH (1987). 1987. ↩︎
Yoshida et al. Transient NKH (1992). 1992. ↩︎
Bank et al. Late-onset NKH (2019). 2019. ↩︎
Camas et al. Diagnostic approach to NKH (2020). 2020. ↩︎
Matsumoto et al. Sodium benzoate therapy (1982). 1982. ↩︎
Kure et al. Valproate contraindication (1991). 1991. ↩︎
Crombez et al. Dextromethorphan in NKH (1995). 1995. ↩︎
Michals-Matalon et al. Dietary therapy in NKH (2019). 2019. ↩︎
Roth et al. Supportive care in NKH (2018). 2018. ↩︎
Coughlin et al. Long-term outcomes in NKH (2021). 2021. ↩︎
Obara et al. Mouse models of NKH (2019). 2019. ↩︎
Pardo et al. Biochemical studies in animal models (2020). 2020. ↩︎